Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Multiple Sclerosis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have central neuropathic pain due to multiple sclerosis (MS) based on the disease diagnostic criteria~* Adult males or females~* Have a score of 4 or greater on the daily 24-hour average pain score~* Females must test negative for pregnancy at study entry~* Complete the daily diaries for at least 70% of the days of the study~* Participants may continue other prescription and nonprescription analgesic pain medications as long as the dose has been stable for 1 month prior to study entry, and they agree to maintain that stable dose throughout the study Disease Diagnostic Criteria:~  * Diagnosis of MS at least 1 year prior to study entry~ * No MS flares or change in disease treatment for the 3 months prior to study entry~ * Daily pain due to MS for a minimum of 3 months prior to study entry~Exclusion Criteria:~* Are currently in a clinical trial of MS disease-modifying therapy~* Have pain that cannot be clearly differentiated from causes other than MS~* Any current or historical diagnosis of mania, bipolar disorder, psychosis, or schizoaffective disorder~* History of substance abuse or dependence~* Are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Duloxetine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).